National Bank of Canada
RAPP

National Bank of Canada’s Rapport Therapeutics RAPP Stock Holding History

National Bank of Canada’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$291 Buy
+7
New +$257 ﹤0.01% 2923

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

National Bank of Canada's RAPP Position: Q2 2026 in Review

National Bank of Canada opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 7 shares worth $291. The stake represents ﹤0.01% of the portfolio and ranks #2923 among its holdings.

161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • National Bank of Canada held 7 shares of Rapport Therapeutics worth $291 as of Q2 2026.
  • Rapport Therapeutics was a new National Bank of Canada position in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2923 holding.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.